Correlation P2Y12 Genetic Polymorphism As Risk Factor of Clopidogrel Resistance in Indonesian Stroke Patients.
P2Y12
antiplatelet
clopidogrel resistance
stroke
Journal
Vascular health and risk management
ISSN: 1178-2048
Titre abrégé: Vasc Health Risk Manag
Pays: New Zealand
ID NLM: 101273479
Informations de publication
Date de publication:
2023
2023
Historique:
received:
19
08
2022
accepted:
15
12
2022
entrez:
6
2
2023
pubmed:
7
2
2023
medline:
8
2
2023
Statut:
epublish
Résumé
Stroke is one of the highest causes of disability and mortality in several countries worldwide. Secondary prevention is important in the management of stroke. Clopidogrel is widely used in Asia as secondary prevention for ischemic stroke, even though several studies in Western show limited data related to clopidogrel resistance in Asia. This study aims to determine the correlation between P2Y12 genetic polymorphism and clopidogrel resistance in Indonesia. This study was conducted on one-year duration, the subjects were chosen through the consecutive sampling method, all subjects were examined for genetics and resistance to clopidogrel. The data were analyzed through statistical analysis, a bivariate analysis was conducted to determine the correlation between several variables and the resistance variable. This study employed resistance diagnostic methods with VerifyNow. Polymorphism of receptor P2Y12 was tested with the Polymerase Chain Reaction method (PCR) and analysis of restriction fragment length polymorphism (RFLP). The genes tested in this study were G52T and C34T. The number of participants in this study was 112. Examination of gene P2Y12 showed that the majority was homozygote, wild-type C34T allele (67%), and G52T (66.1%). There was no significant correlation between clopidogrel resistance and gene G52T and C34T of P2Y12 (p > 0.05). Hb levels significantly correlated with P2Y12 G52T (p = 0.024). Meanwhile, Fatty Liver significantly correlated with P2Y12 C34T (p = 0.037). Indonesia showed a low clopidogrel resistance rate and a very low C34T and G52T allele P2Y12 gene mutation, meaning that Indonesia had low mutations in the P2Y12. This is the cause of clopidogrel resistance in this study only 15%. Therefore, in a region with less clopidogrel resistance, examination of the P2Y12 gene would not give significant results.
Sections du résumé
Background
UNASSIGNED
Stroke is one of the highest causes of disability and mortality in several countries worldwide. Secondary prevention is important in the management of stroke. Clopidogrel is widely used in Asia as secondary prevention for ischemic stroke, even though several studies in Western show limited data related to clopidogrel resistance in Asia. This study aims to determine the correlation between P2Y12 genetic polymorphism and clopidogrel resistance in Indonesia.
Methods
UNASSIGNED
This study was conducted on one-year duration, the subjects were chosen through the consecutive sampling method, all subjects were examined for genetics and resistance to clopidogrel. The data were analyzed through statistical analysis, a bivariate analysis was conducted to determine the correlation between several variables and the resistance variable. This study employed resistance diagnostic methods with VerifyNow. Polymorphism of receptor P2Y12 was tested with the Polymerase Chain Reaction method (PCR) and analysis of restriction fragment length polymorphism (RFLP). The genes tested in this study were G52T and C34T.
Results
UNASSIGNED
The number of participants in this study was 112. Examination of gene P2Y12 showed that the majority was homozygote, wild-type C34T allele (67%), and G52T (66.1%). There was no significant correlation between clopidogrel resistance and gene G52T and C34T of P2Y12 (p > 0.05). Hb levels significantly correlated with P2Y12 G52T (p = 0.024). Meanwhile, Fatty Liver significantly correlated with P2Y12 C34T (p = 0.037).
Conclusion
UNASSIGNED
Indonesia showed a low clopidogrel resistance rate and a very low C34T and G52T allele P2Y12 gene mutation, meaning that Indonesia had low mutations in the P2Y12. This is the cause of clopidogrel resistance in this study only 15%. Therefore, in a region with less clopidogrel resistance, examination of the P2Y12 gene would not give significant results.
Identifiants
pubmed: 36743859
doi: 10.2147/VHRM.S386107
pii: 386107
pmc: PMC9893839
doi:
Substances chimiques
Clopidogrel
A74586SNO7
Platelet Aggregation Inhibitors
0
Purinergic P2Y Receptor Antagonists
0
Receptors, Purinergic P2Y12
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
53-61Informations de copyright
© 2023 Hidayat et al.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
J Neurol Sci. 2009 Dec 15;287(1-2):45-51
pubmed: 19815240
Cardiovasc Drugs Ther. 2022 Aug 9;:
pubmed: 35943672
J Cardiovasc Pharmacol. 2010 Jul;56(1):29-37
pubmed: 20386460
Int J Environ Res Public Health. 2017 Mar 14;14(3):
pubmed: 28335443
Br J Anaesth. 2009 Apr;102(4):492-8
pubmed: 19286767
J Am Coll Cardiol. 2010 Sep 14;56(12):919-33
pubmed: 20828644
J Zhejiang Univ Sci B. 2017 Jan.;18(1):37-47
pubmed: 28070995
Cochrane Database Syst Rev. 2003;(2):CD000029
pubmed: 12804384
Stroke. 2014 Jun;45(6):1839-41
pubmed: 24788972
Circulation. 2003 Aug 26;108(8):989-95
pubmed: 12912815
J Clin Epidemiol. 1988;41(2):105-14
pubmed: 3335877
Int J Cardiol. 2009 Apr 17;133(3):341-5
pubmed: 18485500
Acta Med Acad. 2022 Apr;51(1):29-34
pubmed: 35695400
Adv Clin Exp Med. 2017 Mar-Apr;26(2):343-349
pubmed: 28791856
Cardiol Res Pract. 2017;2017:8062796
pubmed: 28421156
Thromb Res. 2011 Oct;128(4):307-16
pubmed: 21592545
Curr Opin Pharmacol. 2003 Apr;3(2):175-80
pubmed: 12681240
Vasc Health Risk Manag. 2015 Feb 18;11:133-48
pubmed: 25733843
Lancet. 1996 Nov 16;348(9038):1329-39
pubmed: 8918275
Int J Neurosci. 2013 Mar;123(3):143-54
pubmed: 23110469
Intern Med. 2011;50(1):31-5
pubmed: 21212570
J Diabetes Investig. 2019 May;10(3):780-792
pubmed: 30220102
Biotechniques. 2001 Feb;30(2):318-22, 324, 326 passim
pubmed: 11233601
Acta Cardiol. 2015 Oct;70(5):516-21
pubmed: 26567810
Stroke. 2011 Feb;42(2):517-84
pubmed: 21127304
J Am Coll Cardiol. 1998 Oct;32(4):1126-8
pubmed: 9768742
Curr Opin Hematol. 2003 Sep;10(5):333-8
pubmed: 12913786
Stroke. 2009 Apr;40(4):1082-90
pubmed: 19211488
Front Biosci. 2006 May 01;11:1977-86
pubmed: 16368572
J Interv Cardiol. 2011 Dec;24(6):529-34
pubmed: 21919956
JAMA. 2011 Mar 16;305(11):1097-105
pubmed: 21406646
Circulation. 2021 Feb 23;143(8):e254-e743
pubmed: 33501848